Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P01903

UPID:
DRA_HUMAN

ALTERNATIVE NAMES:
MHC class II antigen DRA

ALTERNATIVE UPACC:
P01903; A2BET4; Q30160; Q6IAZ1; Q861I2; Q9TP70

BACKGROUND:
MHC class II antigen DRA plays a pivotal role in the immune system by presenting antigenic peptides to CD4-positive T cells, guiding effective immune responses. It is involved in the presentation of a wide range of peptides, including those from pathogens, tumor cells, and self-proteins, thereby contributing to pathogen clearance, tumor surveillance, and maintenance of self-tolerance. The protein's ability to present peptides derived from different sources underlines its importance in immune regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of MHC class II antigen DRA offers valuable insights into potential therapeutic applications. Its central role in mediating immune responses positions it as a key target for interventions aimed at boosting antitumor immunity or correcting immune dysregulation in autoimmune conditions. Harnessing its potential could lead to innovative approaches in immunotherapy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.